Like my fellow sparring partner, Ryan Fuhrmann, I also consider myself to be a contrarian investor. So I can definitely respect those who've taken a somewhat contrarian approach by buying the down-and-out shares of Pfizer
Ryan makes a good point: Johnson & Johnson is well-diversified, and thus better-protected against downturns (in the stent market, for instance) than a smaller, less-diversified name like Boston Scientific
Don't get me wrong: J&J is a good company. I just happened to peg it as a future underperformer.